Market Closed -
Hong Kong S.E.
01:38:35 13/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
0.105
HKD
|
-25.53%
|
|
+47.89%
|
+156.10%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
511.3
|
519.8
|
282.4
|
177.2
|
215.7
|
145.6
|
Enterprise Value (EV)
1 |
537
|
496.5
|
254.7
|
145.8
|
205
|
176.8
|
P/E ratio
|
-1.76
x
|
-2.26
x
|
-1.76
x
|
-7.07
x
|
-2.09
x
|
-2.68
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.6
x
|
0.76
x
|
0.68
x
|
1.29
x
|
1.27
x
|
1.03
x
|
EV / Revenue
|
1.68
x
|
0.73
x
|
0.62
x
|
1.06
x
|
1.21
x
|
1.24
x
|
EV / EBITDA
|
-3.58
x
|
-7.23
x
|
-15.6
x
|
-2.87
x
|
-2.72
x
|
-4.63
x
|
EV / FCF
|
-8.85
x
|
-13.4
x
|
-1.7
x
|
1.63
x
|
125
x
|
-1.56
x
|
FCF Yield
|
-11.3%
|
-7.45%
|
-58.9%
|
61.3%
|
0.8%
|
-64.1%
|
Price to Book
|
1.3
x
|
1.32
x
|
0.87
x
|
0.6
x
|
1.12
x
|
1.05
x
|
Nbr of stocks (in thousands)
|
7,10,131
|
8,52,131
|
7,84,441
|
7,70,481
|
7,70,481
|
7,70,481
|
Reference price
2 |
0.7200
|
0.6100
|
0.3600
|
0.2300
|
0.2800
|
0.1890
|
Announcement Date
|
28/07/17
|
27/07/18
|
28/04/20
|
21/04/21
|
28/04/22
|
26/04/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
319.2
|
682.5
|
413.3
|
137.9
|
170.1
|
142.1
|
EBITDA
1 |
-150
|
-68.67
|
-16.34
|
-50.75
|
-75.48
|
-38.2
|
EBIT
1 |
-167.9
|
-88.73
|
-18.05
|
-52.31
|
-75.78
|
-38.39
|
Operating Margin
|
-52.6%
|
-13%
|
-4.37%
|
-37.94%
|
-44.56%
|
-27.02%
|
Earnings before Tax (EBT)
1 |
-263.8
|
-194.7
|
-168.4
|
-72.93
|
-100.6
|
-56.4
|
Net income
1 |
-241.9
|
-186.1
|
-165.8
|
-25.22
|
-103
|
-54.27
|
Net margin
|
-75.79%
|
-27.27%
|
-40.12%
|
-18.3%
|
-60.59%
|
-38.21%
|
EPS
2 |
-0.4088
|
-0.2694
|
-0.2045
|
-0.0325
|
-0.1337
|
-0.0704
|
Free Cash Flow
1 |
-60.69
|
-37
|
-150.1
|
89.43
|
1.64
|
-113.4
|
FCF margin
|
-19.01%
|
-5.42%
|
-36.33%
|
64.88%
|
0.96%
|
-79.8%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/07/17
|
27/07/18
|
28/04/20
|
21/04/21
|
28/04/22
|
26/04/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
25.7
|
-
|
-
|
-
|
-
|
31.2
|
Net Cash position
1 |
-
|
23.3
|
27.7
|
31.4
|
10.8
|
-
|
Leverage (Debt/EBITDA)
|
-0.1712
x
|
-
|
-
|
-
|
-
|
-0.8159
x
|
Free Cash Flow
1 |
-60.7
|
-37
|
-150
|
89.4
|
1.64
|
-113
|
ROE (net income / shareholders' equity)
|
-61.7%
|
-70.1%
|
-20.9%
|
-22.2%
|
-42.1%
|
-32.7%
|
ROA (Net income/ Total Assets)
|
-16.5%
|
-9.62%
|
-0.76%
|
-6.33%
|
-12.7%
|
-7.97%
|
Assets
1 |
1,468
|
1,934
|
21,783
|
398.4
|
814.1
|
680.7
|
Book Value Per Share
2 |
0.5500
|
0.4600
|
0.4200
|
0.3800
|
0.2500
|
0.1800
|
Cash Flow per Share
2 |
0.0600
|
0.0800
|
0.0600
|
0.0500
|
0.0500
|
0.0200
|
Capex
1 |
16.5
|
6.31
|
4.36
|
4.52
|
0.36
|
0.63
|
Capex / Sales
|
5.18%
|
0.92%
|
1.06%
|
3.28%
|
0.21%
|
0.44%
|
Announcement Date
|
28/07/17
|
27/07/18
|
28/04/20
|
21/04/21
|
28/04/22
|
26/04/23
|
|
1st Jan change
|
Capi.
|
---|
| +156.10% | 13.9M | | +20.94% | 72.78B | | -1.26% | 24.24B | | +8.80% | 8.59B | | +8.25% | 8.38B | | -19.42% | 8.09B | | +6.47% | 4.81B | | +16.83% | 4.32B | | -1.83% | 4.05B | | +26.97% | 3.79B |
Pharmaceuticals Wholesale
|